Capital Markets Day: Commercial Execution and Innovation in Obesity Care
8
Commercial execution and innovation
Obesity care
Patient-centric strategy designed to activate more people with
obesity, drive HCP engagement and improve market access
Millon
people >650 million people.
650
live with obesity
50
50
650
0
Truth
-10% seek help
~2% are treated
with an AOM
~2.5 million seen by
obesity experts
Treated ~1 million
55
65
with SaxendaⓇ in
2021
Only 25% on treatment
for more than 1 year
13
-2.5———
-1
0.25
Ensure obesity is a healthcare priority
needing medical management
Rethink
ObesityⓇ
direct
care
obesity
SELECT
semaglutide | effects on cardiovascular
outcomes in people with overweight or obesity
About
Weight™
HCP: Healthcare providers; AOM: Anti-obesity medication
Maximize the value of Novo Nordisk's
superior treatment solutions
Marketed product portfolio and pipeline
closing the treatment gaps
Novo NordiskⓇ
CMD22
CAPITAL MARKETS DAYView entire presentation